Drugs@FDA: FDA-Approved Drugs
New Drug Application (NDA): 020326
Company: MEDIMMUNE ONCOLOGY
Company: MEDIMMUNE ONCOLOGY
| Drug Name | Active Ingredients | Strength | Dosage Form/Route | Marketing Status | TE Code | RLD | RS |
|---|---|---|---|---|---|---|---|
| NEUTREXIN | TRIMETREXATE GLUCURONATE | EQ 25MG BASE/VIAL | INJECTABLE;INJECTION | Discontinued | None | No | No |
| NEUTREXIN | TRIMETREXATE GLUCURONATE | EQ 200MG BASE/VIAL | INJECTABLE;INJECTION | Discontinued | None | No | No |
| Action Date | Submission | Supplement Categories or Approval Type | Letters, Reviews, Labels, Patient Package Insert |
Note | Url |
|---|---|---|---|---|---|
| 11/09/2005 | SUPPL-15 | Labeling | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/020326s015lbl.pdf | |
| 06/26/2002 | SUPPL-13 | Labeling | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/20326s11s13lbl.pdf | |
| 06/26/2002 | SUPPL-11 | Labeling | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/20326s11s13lbl.pdf |